MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. More Details
Revenue is forecast to grow 27.13% per year
Currently unprofitable and not forecast to become profitable over the next 3 years
Shareholders have been diluted in the past year
Excellent balance sheet with limited growth.
Search for a company to compare.